使用Player FM应用程序离线!
Novel Cancer Therapeutic Targets and Inhibits Nuclear Beta-Catenin in Desmoid Tumor Study with Rahul Aras Iterion Therapeutics
Manage episode 275412415 series 99915
Rahul Aras, CEO, Iterion Therapeutics, describes their lead product Tegavivint, a potent selective inhibitor of nuclear beta-catenin, a high-value oncology target because of its role in cell proliferation, differentiation, immune evasion and other aspects of cancer development. An early clinical study in patients with the rare disease Desmoid tumors has showed that their tumor stabilized and reversed in size. Progress is being driven by recent understanding of the role of TBL1 in driving oncogenic activity of beta-catenin.
#IterionTherapeutics #Tegavivint #cancer #DesmoidTumors #nuclearbetacatenin #TBL1
1733集单集
Manage episode 275412415 series 99915
Rahul Aras, CEO, Iterion Therapeutics, describes their lead product Tegavivint, a potent selective inhibitor of nuclear beta-catenin, a high-value oncology target because of its role in cell proliferation, differentiation, immune evasion and other aspects of cancer development. An early clinical study in patients with the rare disease Desmoid tumors has showed that their tumor stabilized and reversed in size. Progress is being driven by recent understanding of the role of TBL1 in driving oncogenic activity of beta-catenin.
#IterionTherapeutics #Tegavivint #cancer #DesmoidTumors #nuclearbetacatenin #TBL1
1733集单集
所有剧集
×欢迎使用Player FM
Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。